European Medicines Agency Grants BioMarin's Request for Accelerated Assessment of Valoctocogene Roxaparvovec for Treatment of Severe Hemophilia A

Author's Avatar
May 24, 2021

MAA Resubmission on Track for June 2021

PR Newswire